Abstract:Herein, we described the synthesis of some new phthalazine piperazine‐pyrazole conjugates(6a‐n) and their in vitro anticancer activity against four human cancer cell lines such as PC‐3, MCF‐7, DU‐145, and A‐549. The anticancer activity results reveals that the four compounds 6c, 6h, 6i, and 6n shown promising activity than the standard drug Erlotinib. Furthermore, the in silico studies of compounds 6c, 6h, 6i, and 6n supports the in vitro anticancer results. In addition, ADMET analyses were carried out on four potent compounds and results accordant with the in vitro anticancer and in vitro EGFR tyrosine kinase inhibition data. In this paper, we describe the synthesis of some new quinoxaline‐piperazine‐oxazole amide conjugates 6a‐n from 3‐chloroquinoxaline‐2‐carbonitrile using well‐known reaction sequences. The synthesized compounds were characterized by 1H NMR,13C NMR, and mass spectral analysis. The compounds were tested for their in vitro antiproliferative activity toward four different cancer cell lines such as PC‐3, MCF‐7, DU‐145, and A‐549 by MTT method. The compounds, 6c, 6h, 6i, and 6n were found to be more potent than the standard Erlotinib. In vitro tyrosine kinase EGFR inhibition studies using four potent compounds revealed that 6n has double inhibiting tendency with value IC50 of 0.22 μM and 6h with value of IC50 0.27 μM compared to reference compound. Molecular docking studies of active compounds, 6c, 6h, 6i, and 6n on EGFR receptor suggested that all the compounds have more binding energies than that of Erlotinib. Furthermore, the in silico pharmacokinetic profile was accomplished for the active compounds, 6c, 6h, 6i, and 6n using SWISS/ADME and pk CSM, whereas compounds, 6h, 6i, and 6c followed Lipinski rule, Veber rule, Egan rule and Muegge rule. The remaining compound 6n did not follow Lipinski rule, Ghose rule because one common violation, that is, because of high molecular weight (MW > 350).

Design, Synthesis and Anti-Tumor Activities of Cyclic Phosphoramidate Mustard-Quinazoline Conjugates

Design, Synthesis and Biological Evaluation of Quinazoline-Phosphoramidate Mustard Conjugates As Anticancer Drugs

Synthesis and in Vitro Anticancer Activity of 6,7-Methylenedioxy (or 5-Hydroxy-6-methoxy)-2-(substituted Selenophenyl)Quinolin-4-One Analogs

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Synthesis, anticancer evaluation and mechanism studies of novel indolequinone derivatives of ursolic acid

Design, synthesis and antitumor activity of triphenylphosphonium-linked derivatives of quinazolinone

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents

Novel Penta-1,4-Diene-3-One Derivatives Containing Quinazoline And Oxime Ether Fragments: Design, Synthesis And Bioactivity

Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway

Synthesis, Biological Evaluation and Molecular Docking Studies of Amide-Coupled Benzoic Nitrogen Mustard Derivatives As Potential Antitumor Agents.

Structure-based design, synthesis and biological evaluation of N-substituted 6H-thiochromeno[2,3–c]quinolin-12(12H)-ones as potential breast cancer drugs

Design, synthesis, and evaluation of antitumor activity of quinazoline derivatives containing different terminal segments of basic amine groups

Synthesis, Molecular Modeling and Biological Evaluation of 2-Aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3h)-thione Quinolone Derivatives As Novel Anticancer Agent

Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives As Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.

Design and Synthesis of 4,6-Substituted-(diaphenylamino)quinazolines As Potent Egfr Inhibitors with Antitumor Activity

Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluations

New quinoxaline‐piperazine‐oxazole conjugates: Synthesis, in vitro anticancer, in silico ADMET, and molecular docking studies

Design, synthesis and biological evaluation of 2,3-dihydro-[1,4]dioxino[2,3-f]quinazoline derivatives as EGFR inhibitors